A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

This was the stock's second consecutive day of losses.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to Two Sigma Investments. Two Sigma Investments, LP ...

Eli Lilly & Co. is adding Alzheimer’s disease resources to the online platform it launched a year ago to sell obesity, diabetes and migraine medicines. Patients will now be able to use ...

He also recommends avoiding Eli Lilly (LLY), as its tremendous revenue growth is hard to repeat. To watch more expert insights and analysis on the latest market action, check out more Market ...

Cooper Flagg #2 of the Duke Blue Devils defends Jason Asemota #5 of the Baylor Bears during the second round of the 2025 NCAA ...

Eli Lilly's weight loss drug Mounjaro, launched last week in India at a significantly lower price than in the US, may still be out of reach for most Indian patients, doctors treating obesity told ...

Crunching the data, the news looks relatively worse for Novo Nordisk and relatively better for rivals Eli Lilly and Him & Hers Health. First, Novo Nordisk is expanding its program to sell Wegovy ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher In this article, we are ...